CCR5 Is required for regulation of alloreactive T-cell responses to single class II MHC-mismatched murine cardiac grafts

American Journal of Transplantation

Volumn 9, Issue 10, 2009, Pages 2251-2261

  Nozaki, T ^a   Rosenblum, J M ^b,c   Schenk, A D ^b,c   Ishii, D ^b   Fairchild, R L ^b,c  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^b LERNER RESEARCH INSTITUTE   (United States)

^c CASE WESTERN RESERVE UNIVERSITY   (United States)

Author keywords

CD4 T cells; Chemokine receptors; Transplantation immunology

Indexed keywords

CHEMOKINE RECEPTOR CCR5; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; TRANSCRIPTION FACTOR FOXP3;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; C57BL 6 MOUSE; CARDIAC GRAFT REJECTION; CD4+ CD25+ T LYMPHOCYTE; GRAFT RECIPIENT; GRAFT SURVIVAL; HEART GRAFT; HEART TRANSPLANTATION; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; LYMPHOCYTIC INFILTRATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SPLEEN; T LYMPHOCYTE ACTIVATION; WILD TYPE;

ANIMALS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HEART TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS II; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; RECEPTORS, CCR5; T-LYMPHOCYTES, REGULATORY;

EID: 70349212424     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2009.02786.x     Document Type: Article

References (37)

1. Rosenberg AS, Singer A. Cellular basis of skin allograft rejection: An in vivo model of immune-mediated tissue destruction. Annu Rev Immunol 1992 10 : 333 358.
2. Sho M, Yamada A, Najafian N et al. Physiological mechanisms of regulating alloimmunity: Cytokines, CTLA-4, CD25 +cells, and the alloreactive T cell clone size. J Immunol 2002 169 : 3744 3751.
3. Koga S, Auerbach MB, Engeman TM, Novick AC, Toma H, Fairchild RL. T cell infiltration into class II MHC-disparate allografts and acute rejection is dependent on the IFN-gamma-induced chemokine Mig. J Immunol 1999 163 : 4878 4885.
4. Watarai Y, Koga S, Paolone DR et al. Intraallograft chemokine RNA and protein during rejection of MHC-matched/multiple minor histocompatibility- disparate skin grafts. J Immunol 2000 164 : 6027 6033.
5. Yun JJ, Fischbein MP, Whiting D et al. The role of MIG/CXCL9 in cardiac allograft vasculopathy. Am J Pathol 2002 161 : 1307 1313.
6. McKenzie IF, Morgan GM, Sandrin MS, Michaelides MM, Melvold RW, Kohn HI. B6.C-H-2bm12. A new H-2 mutation in the I region in the mouse. J Exp Med 1979 150 : 1323 1338.
7. Mengle-Gaw L, Conner S, McDevitt HO, Fathman CG. Gene conversion between murine class II major histocompatibility complex loci. Functional and molecular evidence from the bm 12 mutant. J Exp Med 1984 160 : 1184 1194.
8. Schenk S, Kish DD, He C et al. Alloreactive T cell responses and acute rejection of single class II MHC-disparate heart allografts are under strict regulation by CD4+ CD25+ T cells. J Immunol 2005 174 : 3741 3748.
9. El-Sawy T, NM Fahmy, RL Fairchild. Chemokines: Directing leukocyte infiltration into allografts. Curr Opin Immunol 2002 14 : 562 568.
10. Hancock WW. Chemokine receptor-dependent alloresponses. Immunol Rev 2003 196 : 37 50.
11. Amano H, Bickerstaff A, Orosz CG, Novick AC, Toma H, Fairchild RL. Absence of recipient CCR5 promotes early and increased allospecific antibody responses to cardiac allografts. J Immunol 2005 174 : 6499 6508.
12. Bickerstaff A, Nozaki T, Wang JJ et al. Acute humoral rejection of renal allografts in CCR5(-/-) recipients. Am J Transplant 2008 8 : 557 566.
13. Nozaki T, Amano H, Bickerstaff A et al. Antibody-mediated rejection of cardiac allografts in CCR5-deficient recipients. J Immunol 2007 179 : 5238 5245.
14. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973 16 : 343 350.
15. Li Q, Wang Y, Yi T et al. Technique for retransplanting heterotopic heart grafts in mice. Microsurgery 2004 24 : 465 467.
16. Afanasyeva M, Georgakopoulos D, Belardi DF et al. Quantitative analysis of myocardial inflammation by flow cytometry in murine autoimmune myocarditis: Correlation with cardiac function. Am J Pathol 2004 164 : 807 815.
17. Wysocki CA, Jiang Q, Panoskaltsis-Mortari A et al. Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. Blood 2005 106 : 3300 3307.
18. Zhao D, Zhang C, Yi T et al. In vivo-activated CD103+CD4+ regulatory T cells ameliorate ongoing chronic graft-versus-host disease. Blood 2008 112 : 2129 2138.
19. Curiel TJ, Coukos G, Zou L et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004 10 : 942 949.
20. Annunziato F, Cosmi L, Liotta F et al. Phenotype, localization, and mechanism of suppression of CD4(+)CD25(+) human thymocytes. J Exp Med 2002 196 : 379 387.
21. Gavin M, Rudensky A. Control of immune homeostasis by naturally arising regulatory CD4+ T cells. Curr Opin Immunol 2003 15 : 690 696.
22. Gavin MA, Clarke SR, Negrou E, Gallegos A, Rudensky A. Homeostasis and anergy of CD4(+)CD25(+) suppressor T cells in vivo. Nat Immunol 2002 3 : 33 41.
23. Stephens GL, Andersson J, Shevach EM. Distinct subsets of FoxP3+ regulatory T cells participate in the control of immune responses. J Immunol 2007 178 : 6901 6911.
24. Joffre O, Santolaria T, Calise D et al. Prevention of acute and chronic allograft rejection with CD4+CD25+Foxp3+ regulatory T lymphocytes. Nat Med 2008 14 : 88 92.
25. Xia G, He J, Leventhal JR. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am J Transplant 2008 8 : 298 306.
26. Gregori S, Casorati M, Amuchastegui S, Smiroldo S, Davalli AM, Adorini L. Regulatory T cells induced by 1 alpha,25-dihydroxyvitamin D3 and mycophenolate mofetil treatment mediate transplantation tolerance. J Immunol 2001 167 : 1945 1953.
27. Zheng XX, Sanchez-Fueyo A, Sho M, Domenig C, Sayegh MH, Strom TB. Favorably tipping the balance between cytopathic and regulatory T cells to create transplantation tolerance. Immunity 2003 19 : 503 514.
28. Graca L, Cobbold SP, Waldmann H. Identification of regulatory T cells in tolerated allografts. J Exp Med 2002 195 : 1641 1646.
29. Wood KJ, Ushigome H, Karim M, Bushell A, Hori S, Sakaguchi S. Regulatory cells in transplantation. Novartis Found Symp 2003 252 : 177 188 discussion 188 193, 203 110.
30. Lee I, Wang L, Wells AD, Dorf ME, Ozkaynak E, Hancock WW. Recruitment of Foxp3 +T regulatory cells mediating allograft tolerance depends on the CCR4 chemokine receptor. J Exp Med 2005 201 : 1037 1044.
31. Chen L, Wang T, Zhou P et al. TLR engagement prevents transplantation tolerance. Am J Transplant 2006 6 : 2282 2291.
32. Porrett PM, Yuan X, LaRosa DF et al. Mechanisms underlying blockade of allograft acceptance by TLR ligands. J Immunol 2008 181 : 1692 1699.
33. Moreira AP, Cavassani KA, Massafera Tristao FS et al. CCR5-dependent regulatory T cell migration mediates fungal survival and severe immunosuppression. J Immunol 2008 180 : 3049 3056.
34. Yurchenko E, Tritt M, Hay V, Shevach EM, Belkaid Y, Piccirillo CA. CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence. J Exp Med 2006 203 : 2451 2460.
35. Hildebrandt GC, Corrion LA, Olkiewicz KM et al. Blockade of CXCR3 receptor: Ligand interactions reduces leukocyte recruitment to the lung and the severity of experimental idiopathic pneumonia syndrome. J Immunol 2004 173 : 2050 2059.
36. Schnickel GT, Bastani S, Hsieh GR et al. Combined CXCR3/CCR5 blockade attenuates acute and chronic rejection. J Immunol 2008 180 : 4714 4721.
37. Gao W, Faia KL, Csizmadia V et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001 72 : 1199 1205.